Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jon P Gockerman

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Clinical Lymphoma|September 30, 2004
Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphomaJeffrey Talbot, Valerie K Ibom, David A Rizzieri, et al.
Cancer Investigation|February 15, 2013
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myelomaLauren A Held, David Rizzieri, Gwynn D Long, et al.
Cancer|May 20, 2009
Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemiaDavid A Rizzieri, Jenny A O'Brien, Gloria Broadwater, et al.
Blood|March 9, 2007
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801Daniel J DeAngelo, Daohai Yu, Jeffrey L Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2002
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphomaAdam J Bass, Jon P Gockerman, Eve Hammett, et al.
Leukemia & Lymphoma|August 1, 2002
Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemiaSteven L McCune, Jon P Gockerman, Joseph O Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemiaDavid A Rizzieri, Adam J Bass, Gary L Rosner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical responseWilliam Larry Gluck, Deborah Hurst, Alan Yuen, et al.
Cancer|May 26, 2004
Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphomaDavid A Rizzieri, Gregory J Sand, Dean McGaughey, et al.
Leukemia & Lymphoma|July 19, 2013
Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studiesDaphne R Friedman, Mark C Lanasa, Patricia H Davis, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Clinical Lymphoma|September 30, 2004
Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphomaJeffrey Talbot, Valerie K Ibom, David A Rizzieri, et al.
Cancer Investigation|February 15, 2013
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myelomaLauren A Held, David Rizzieri, Gwynn D Long, et al.
Cancer|May 20, 2009
Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemiaDavid A Rizzieri, Jenny A O'Brien, Gloria Broadwater, et al.
Blood|March 9, 2007
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801Daniel J DeAngelo, Daohai Yu, Jeffrey L Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2002
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphomaAdam J Bass, Jon P Gockerman, Eve Hammett, et al.
Leukemia & Lymphoma|August 1, 2002
Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemiaSteven L McCune, Jon P Gockerman, Joseph O Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemiaDavid A Rizzieri, Adam J Bass, Gary L Rosner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical responseWilliam Larry Gluck, Deborah Hurst, Alan Yuen, et al.
Cancer|May 26, 2004
Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphomaDavid A Rizzieri, Gregory J Sand, Dean McGaughey, et al.
Leukemia & Lymphoma|July 19, 2013
Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studiesDaphne R Friedman, Mark C Lanasa, Patricia H Davis, et al.
Pageof 6